Twelve‐month analysis of real‐world evidence from a telehealth obesity‐treatment provider using antiobesity medications
Authors' conclusion
This real-world analysis of a telehealth-delivered obesity-treatment program demonstrated outcomes consistent with recent phase 3 clinical trials of AOMs, suggesting generalizability beyond clinical trial and in-person settings.
Study context
- Population
- Adults initiating AOM treatment with the with the WeightWatchers (WW) Clinic telehealth program, January 2022–July 2023; 88.6% female, mean BMI 36.9 kg/m²
- Participants
- 53,590 adults
- Outcome
- Change in body weight
- Follow-up
- 12 months
Methodological detailsreal-world data, telehealth
- Real-world data
- Telehealth
Main finding
As reported in the abstract
Average weight loss · 3, 6, 9 and 12 months
Weight loss at 3 months (n = 37,565)
8.9%
Weight loss at 6 months (n = 24,140)
14.1%
Weight loss at 9 months (n = 15,169)
17.7%
Weight loss at 12 months (n = 6089)
19.4%
Observational data: associations, not effects.
Further findings
Program retention (patients with ≥3, 6, 9 and 12 months from enrollment)
- Retention at 3 months
- 78% (n = 39,907/51,247)
- Retention at 6 months
- 63% (n = 25,515/40,203)
- Retention at 9 months
- 58% (n = 15,472/26,794)
- Retention at 12 months
- 77% (n = 6459/8394)
Treatment duration
- Mean (SD) treatment duration
- 5.3 (4.3) months
Medication usage patterns
- GLP-1 RA-based treatments were predominant
Safety
- Side effects consistent with the medication classes used; frequency declined over time
Original publication
Twelve‐month analysis of real‐world evidence from a telehealth obesity‐treatment provider using antiobesity medications. Obesity (Silver Spring). Published 30 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →